616 related articles for article (PubMed ID: 33428978)
1. Facial and neck erythema associated with dupilumab treatment: A systematic review.
Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
[TBL] [Abstract][Full Text] [Related]
2. A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis.
Jaros J; Hendricks AJ; Shi VY; Lio PA
Dermatitis; 2020; 31(3):169-177. PubMed ID: 32355092
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab facial redness: histologic characterization on a series of four cases.
Dybała A; Sernicola A; Gomes V; Carnicelli G; Muharremi R; Grieco T
Immunotherapy; 2022 Mar; 14(4):183-188. PubMed ID: 34933583
[TBL] [Abstract][Full Text] [Related]
4. Rosacea associated with dupilumab therapy.
Heibel HD; Hendricks AJ; Foshee JP; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):114-116. PubMed ID: 31132923
[No Abstract] [Full Text] [Related]
5. Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians.
Muzumdar S; Skudalski L; Sharp K; Waldman RA
Am J Clin Dermatol; 2022 Jan; 23(1):61-67. PubMed ID: 34855151
[TBL] [Abstract][Full Text] [Related]
6. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis.
Yamane MLM; Belsito DV; Glass LRD
Orbit; 2019 Oct; 38(5):390-394. PubMed ID: 30628518
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort.
Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V
Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488
[TBL] [Abstract][Full Text] [Related]
8. Facial erythema in patients with atopic dermatitis treated with Dupilumab - a descriptive study of morphology and Aetiology.
Ahn J; Lee DH; Na CH; Shim DH; Choi YS; Jung HJ; Simpson EL
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2140-2152. PubMed ID: 35695074
[TBL] [Abstract][Full Text] [Related]
9. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing.
Ashbaugh AG; Murase EM; Raffi J; Botto N; Murase JE
Dermatitis; 2022 Jan-Feb 01; 33(1):51-61. PubMed ID: 35029349
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.
de Wijs LEM; Nguyen NT; Kunkeler ACM; Nijsten T; Damman J; Hijnen DJ
Br J Dermatol; 2020 Oct; 183(4):745-749. PubMed ID: 31749159
[TBL] [Abstract][Full Text] [Related]
12. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
Francuzik W; Alexiou A; Worm M
Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
[No Abstract] [Full Text] [Related]
13. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
15. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
[TBL] [Abstract][Full Text] [Related]
16. Allergic contact dermatitis to Compositae: A possible cause of dupilumab-associated facial and neck dermatitis in atopic dermatitis patients?
Napolitano M; Fabbrocini G; Patruno C
Contact Dermatitis; 2021 Oct; 85(4):473-474. PubMed ID: 33988858
[No Abstract] [Full Text] [Related]
17. Angioedema: A potential complication of dupilumab in atopic dermatitis.
Fritz AL; Lacy FA; Morrell DS
Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
[TBL] [Abstract][Full Text] [Related]
18. Observation of the clinical features of dupilumab-associated facial erythema.
Wu H; Zhang W; Wu Z; Shen Y; Zhang L; Yang M; Ren Y; Mao F
Postepy Dermatol Alergol; 2023 Dec; 40(6):741-746. PubMed ID: 38282880
[TBL] [Abstract][Full Text] [Related]
19. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
20. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review.
Raffi J; Suresh R; Botto N; Murase JE
J Am Acad Dermatol; 2020 Jan; 82(1):132-138. PubMed ID: 31562940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
